Our data thus provide an explanation why oncogenic mutations have only been reported in B cell lymphoma, rather than tumors arising from myeloid cells, whose MyD88s induction loop possibly renders them more resistant to MyD88 pathway induced NF-κB activity. Here, MYD88 is linked to B-cell non-Hodgkin lymphoma.